Teladoc (TDOC) Form 144 shows insider sale of 4,700 vested shares for $35,650.91
Rhea-AI Filing Summary
Teladoc Health, Inc. (TDOC) Form 144 summary: This notice reports a proposed sale of 4,700 common shares through Fidelity Brokerage Services with an aggregate market value of $35,650.91, to be executed approximately on 09/02/2025 on the NYSE. The shares were acquired on 08/29/2025 as restricted stock vesting and were paid as compensation. The filing also discloses a prior sale by the same account: 4,653 shares sold on 06/02/2025 for $31,919.58. The filing includes the total number of shares outstanding reported as 176,690,662 and contains the required certification that the seller is not aware of undisclosed material adverse information.
Positive
- Complete disclosure of proposed sale details including broker, share count, aggregate market value, and exchange
- Acquisition method stated as restricted stock vesting and payment classified as compensation, improving transparency
- Prior sale disclosed (4,653 shares for $31,919.58), showing historical continuity in filings
Negative
- None.
Insights
TL;DR: Routine insider disposition filing; small number of shares relative to outstanding common stock suggests limited market impact.
The Form 144 documents a proposed sale of 4,700 shares acquired via restricted stock vesting and marked as compensation, with an approximate market value of $35,650.91. The filing follows a prior sale of 4,653 shares that yielded $31,919.58. For investors, this type of disclosure signals an insider selling vested compensation rather than an operational development. The magnitude disclosed is small in absolute dollar terms and compared to the stated 176,690,662 shares outstanding, indicating low direct impact on float or liquidity.
TL;DR: Filing meets Rule 144 disclosure obligations; provides transparency on insider compensation-derived sales.
The notice identifies the broker, sale timing, acquisition method (restricted stock vesting) and prior disposals, and includes the standard insider certification about material nonpublic information. This is a routine compliance disclosure that documents an insider monetizing vested equity awarded as compensation. The record of both the proposed sale and the earlier June sale is consistent with required transparency under securities rules.